Evaluation of a live-attenuated human parainfluenza type 1 vaccine in adults and children

Journal of the Pediatric Infectious Diseases Society

Volumn 4, Issue 4, 2015, Pages e143-e146

  Karron, Ruth A ^a   Mateo, Jocelyn San ^a   Thumar, Bhagvanji ^a   Schaap Nutt, Anne ^b   Buchholz, Ursula J ^b   Schmidt, Alexander C ^b   Bartlett, Emmalene J ^b   Murphy, Brian R ^b   Collins, Peter L ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Children; HPIV 1 vaccine; Lower respiratory tract illness

Indexed keywords

COMPLEMENTARY DNA; HEMAGGLUTINATION INHIBITING ANTIBODY; PARAINFLUENZA VACCINE; PLACEBO; LIVE VACCINE; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; FEVER; HUMAN; HUMAN EXPERIMENT; HUMAN PARAINFLUENZA VIRUS 1; INFANT; NORMAL HUMAN; PARAINFLUENZA VIRUS INFECTION; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHINORRHEA; SORE THROAT; VACCINATION; BLOOD; CLINICAL TRIAL; PARAMYXOVIRIDAE INFECTIONS; PRESCHOOL CHILD;

ADULT; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; HUMANS; INFANT; PARAINFLUENZA VACCINES; PARAINFLUENZA VIRUS 1, HUMAN; PARAMYXOVIRIDAE INFECTIONS; VACCINES, ATTENUATED;

EID: 85006201768     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/piu104     Document Type: Article

References (11)

1. Denny FW, Murphy TF, Clyde WA Jr, et al. Croup: an 11-year study in a pediatric practice. Pediatrics 1983; 71:871-6.
2. Reed G, Jewett PH, Thompson J, et al. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old. J Infect Dis 1997; 175:807-13.
3. Schmidt AC, Schaap-Nutt A, Bartlett EJ, et al. Progress in the development of human parainfluenza virus vaccines. Expert Rev Respir Med 2011; 5:515-26.
4. Weinberg GA, Hall CB, Iwane MK, et al. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr 2009; 154:694-9.
5. Karron RA, Buchholz UJ, Collins PL. Live-attenuated respiratory syncytial virus vaccines. Curr Top Microbiol Immunol 2013; 372:259-84.
6. Bartlett EJ, Castano A, Surman SR, et al. Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes. Virol J 2007; 4:67.
7. Surman SR, Collins PL, Murphy BR, Skiadopoulos MH. An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials. J Virol Methods 2007; 141:30-3.
8. Karron RA, Wright PF, Hall SL, et al. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis 1995; 171:1107-14.
9. Karron RA, Makhene M, Gay K, et al. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two-to six-monthold infants. Pediatr Infect Dis J 1996; 15:650-4.
10. Karron RA, Thumar B, Schappell E, et al. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. Vaccine 2012; 30:3975-81.
11. Englund JA, Karron RA, Cunningham CK, et al. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children. Vaccine 2013; 31:5706-12.